Skip to main content
OpenTrials
Completed

NCT Number: NCT04884308

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

This is pilot study of the immunologic effects of intradermal Bacille Calmette-Guerin (BCG) vaccination of adults with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and healthy volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Johns Hopkins University

Baltimore, Maryland, 21287, United States

About this study

This single-site, open-label clinical trial to investigate the immune effects of BCG vaccination in adults with cystic fibrosis, non-cystic fibrosis bronchiectasis and healthy volunteers by measuring pre and post vaccination immune responses, BCG uptake and protection against infections, including nontuberculous mycobacteria (NTM). This study will also gather data on study feasibility, tolerability, and safety.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(CF and non-CF bronchiectasis):

  • Confirmed diagnosis of either CF or non-CF bronchiectasis
  • Forced expiratory volume over one second (FEV1) > 40%
  • Willingness to participate in the study after all aspects of the protocol have been explained and written informed consent obtained.
  • Available for the study duration, including all planned follow-up visits

Inclusion criteria

(Healthy Volunteers):

  • Negative HIV enzyme-linked immunosorbent assay (ELISA) and confirmatory test at screening.
  • Willingness to participate in the study after all aspects of the protocol have been explained and written informed obtained.
  • Available for the study duration, including all planned follow-up visits

Exclusion criteria

(All arms):

  • Current or prior history of active or latent tuberculosis (TB) (per report, not formally tested) or NTM infection
  • Prior BCG vaccination
  • Previous vaccine in the past 4 weeks
  • History of severe anaphylaxis to any vaccine or vaccine components
  • History of organ/bone marrow transplantation or other immunosuppressing condition, including HIV
  • Immunosuppressing drugs (including oral corticosteroids equivalent to >10mg of prednisone for 5 days) in the 30 days prior to study enrollment
  • Cirrhosis or portal hypertension
  • Pregnant or breastfeeding
  • Receipt of another investigational product in the last 28 days or planned receipt during this study
  • Has any other condition that, in the opinion of the principal investigator, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives.

Treatment and study plan

BCG TICE Vaccine

Biological

Intradermal vaccination with BCG TICE

Primary outcomes

  1. BCG Uptake

    Time frame: 3 months

    Change in concentration of interferon (IFN) gamma levels in blood after Bacille Calmette-Guérin (BCG) incubation relative to baseline as measured by SFUs. Spot forming units (SFU) is a measure of immune response of mononuclear cells in response to M. avium lysate. Higher values indicate a stronger immune response.

Sponsors and collaborators

Lead sponsor

Johns Hopkins University

Other

Collaborators

  • Cystic Fibrosis Foundation

Registry information

Official study title

Effects of BCG Vaccine on the Immune System of Individuals With Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis, and Healthy Volunteers

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
May 12, 2021
Registry last updated
Feb 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.